|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| A61K 39/00 | (2006.01) | ||
| A61K 47/68 | (2017.01) |
| (11) | Number of the document | 3415531 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18163942.8 |
| Date of filing the European patent application | 2012-05-24 | |
| (97) | Date of publication of the European application | 2018-12-19 |
| (45) | Date of publication and mention of the grant of the patent | 2023-09-06 |
| (46) | Date of publication of the claims translation | 2023-09-25 |
| (30) | Number | Date | Country code |
| 201161490732 P | 2011-05-27 | US | |
| 201261647196 P | 2012-05-15 | US |
| (72) |
ALGATE, Paul , US
CLEGG, Stephanie Jane , GB
CRAIGEN, Jennifer L. , GB
HAMBLIN, Paul Andrew , GB
LEWIS, Alan Peter , GB
PARMAR, Radha Shah , GB
MAYES, Patrick , US
WATTAM, Trevor Anthony Kenneth , GB
|
| (73) |
Glaxo Group Limited ,
GSK Medicines Research Centre
Gunnels Wood Road, Stevenage SG1 2NY,
GB
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | BCMA (CD269/TNFRSF17) – surišantys baltymai |
| BCMA (CD269/TNFRSF17) - BINDING PROTEINS |
| Payment date | Validity (years) | Amount | |
| 2026-04-21 | 15 | 289.00 EUR |
| 2027-05-24 |